MiMedx Group (NASDAQ:MDXG) Stock Jumps 7.1% – What’s Next?

Posted by Brenda Bartman on Oct 24th, 2026

Shares of MiMedx Group, Inc (NASDAQ:MDXG – Get Free Report) shot up 7.1% during mid-day trading on Thursday. The company traded as high as $3.97 and last traded at $4.0050. Approximately 384,370 shares were traded during trading, a decline of 70% from the average session volume of 1,288,983 shares. The stock had previously closed at $3.74.

Analyst Ratings Changes

A number of analysts recently weighed in on MDXG shares. Raymond James Financial set a $8.00 price target on MiMedx Group in a research note on Monday, August 17th. Cantor Fitzgerald reiterated an “overweight” rating on shares of MiMedx Group in a research report on Tuesday, September 15th. Wall Street Zen raised shares of MiMedx Group from a “sell” rating to a “hold” rating in a research note on Saturday, August 29th. Seaport Research Partners cut shares of MiMedx Group to a “neutral” rating in a research note on Monday, August 17th. Finally, Craig Hallum increased their price target on shares of MiMedx Group from $6.00 to $8.00 and gave the company a “buy” rating in a report on Thursday, August 27th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, MiMedx Group has a consensus rating of “Moderate Buy” and a consensus target price of $8.57.

Get Our Latest Stock Analysis on MDXG

MiMedx Group Trading Down 0.5%

The firm has a market cap of $569.92 million, a PE ratio of 97.77 and a beta of 1.18. The business has a 50-day moving average price of $4.53 and a two-hundred day moving average price of $4.08. The company has a debt-to-equity ratio of 0.07, a current ratio of 5.33 and a quick ratio of 4.79.

MiMedx Group (NASDAQ:MDXG – Get Free Report) last released its quarterly earnings data on Wednesday, July 29th. The company reported ($0.05) EPS for the quarter, hitting the consensus estimate of ($0.05). MiMedx Group had a net margin of 1.76% and a return on equity of 12.09%. The business had revenue of $64.36 million for the quarter, compared to analyst estimates of $63.46 million. Analysts forecast that MiMedx Group, Inc will post -0.10 EPS for the current year.

Institutional Investors Weigh In On MiMedx Group

A number of institutional investors and hedge funds have recently bought and sold shares of MDXG. Isthmus Partners LLC raised its position in shares of MiMedx Group by 3.5% in the third quarter. Isthmus Partners LLC now owns 549,411 shares of the company’s stock valued at $2,560,000 after buying an additional 18,702 shares during the last quarter. Quadrant Capital Group LLC lifted its stake in shares of MiMedx Group by 59.8% during the third quarter. Quadrant Capital Group LLC now owns 141,091 shares of the company’s stock valued at $662,000 after buying an additional 52,824 shares during the period. Abel Hall LLC boosted its position in MiMedx Group by 18.0% during the third quarter. Abel Hall LLC now owns 80,573 shares of the company’s stock worth $375,000 after acquiring an additional 12,284 shares during the last quarter. NorthCrest Asset Manangement LLC acquired a new stake in MiMedx Group during the third quarter worth approximately $63,000. Finally, GAMMA Investing LLC boosted its position in MiMedx Group by 2,422.5% during the third quarter. GAMMA Investing LLC now owns 7,719 shares of the company’s stock worth $36,000 after acquiring an additional 7,413 shares during the last quarter. Hedge funds and other institutional investors own 79.15% of the company’s stock.

MiMedx Group Company Profile

(Get Free Report)

MiMedx Group, Inc (NASDAQ: MDXG) is a biotechnology company focused on developing and commercializing human placental tissue allografts for wound care and other medical applications. The company’s products are derived from donated placental tissue and are processed using its proprietary PURION technology platform.

MiMedx’s portfolio includes tissue-based products such as EPIFIX and EPICORD, which are used primarily by healthcare professionals in the management of chronic and acute wounds, including diabetic foot ulcers and other hard-to-heal wounds.